View Older Stories View More Recent Stories

Nov 14, 2018 09:56AM Form 13F-HR venBio Partners L.P. For: Sep 30
Oct 19, 2018 07:30AM TP Therapeutics Completes $80 Million Mezzanine Financing Co-Led by Foresite Capital and venBio Partners
Oct 17, 2018 08:00AM Akero Therapeutics Expands Leadership Team
Sep 18, 2018 05:20PM Form 4 IMMUNOMEDICS INC For: Apr 02 Filed by: venBio Select Advisor LLC
Sep 11, 2018 07:00AM Andrew Cheng, MD, PhD Joins Akero Therapeutics as President and Chief Executive Officer
Sep 7, 2018 01:32PM Form D/A venBio Select Fund Ltd.
Sep 7, 2018 01:06PM Form D/A venBio Select Fund LLC
Sep 6, 2018 06:00AM Allogene Therapeutics Completes a $120 Million Private Financing
Aug 14, 2018 03:40PM Form 13F-HR venBio Partners L.P. For: Jun 30
Aug 14, 2018 11:26AM Form 13F-HR venBio Select Advisor For: Jun 30
Jun 26, 2018 06:00AM Precision BioSciences Raises $110M to Advance ARCUS Genome Editing Programs
Jun 25, 2018 07:00AM Akero Therapeutics Closes $65 Million Series A Financing to Advance New Treatments for Serious Metabolic Diseases
Jun 19, 2018 04:06PM Form SC 13D/A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
Jun 15, 2018 02:05PM Form SC 13D/A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
Jun 15, 2018 02:03PM Form 4 IMMUNOMEDICS INC For: Jun 15 Filed by: venBio Select Advisor LLC
Jun 13, 2018 05:19PM Form D venBio Global Strategic
Jun 12, 2018 01:58PM Form 4 Mirati Therapeutics, For: Jun 11 Filed by: venBio Select Advisor LLC
Jun 6, 2018 07:30AM Metacrine Completes $65 Million Series C Financing
May 15, 2018 12:52PM Form 13F-HR venBio Select Advisor For: Mar 31
May 8, 2018 04:01PM Ligand Reports First Quarter 2018 Financial Results
Apr 25, 2018 02:09PM Form 13F-HR venBio Partners L.P. For: Mar 31
Apr 25, 2018 01:43PM Form 13F-HR venBio Partners L.P. For: Dec 31
Mar 30, 2018 09:00AM Ligand Enters into Agreement with venBio to Make Worldwide OmniAb® Platform License Accessible to Portfolio Companies
Feb 14, 2018 11:43AM Form 13F-HR venBio Select Advisor For: Dec 31
Feb 12, 2018 04:26PM Form SC 13G/A Oncobiologics, Inc. Filed by: venBio Select Advisor LLC
Feb 12, 2018 04:25PM Form SC 13G/A ALIMERA SCIENCES INC Filed by: venBio Select Advisor LLC
Feb 12, 2018 04:23PM Form SC 13G FENNEC PHARMACEUTICALS Filed by: venBio Select Advisor LLC
Feb 12, 2018 04:19PM Form SC 13G Intec Pharma Ltd. Filed by: venBio Select Advisor LLC
Feb 12, 2018 04:18PM Form SC 13G AMICUS THERAPEUTICS INC Filed by: venBio Select Advisor LLC
Feb 12, 2018 04:15PM Form SC 13G CATALYST BIOSCIENCES, Filed by: venBio Select Advisor LLC
Feb 12, 2018 04:14PM Form SC 13G Teligent, Inc. Filed by: venBio Select Advisor LLC
Feb 12, 2018 04:14PM Form SC 13G ASSEMBLY BIOSCIENCES, Filed by: venBio Select Advisor LLC
Feb 12, 2018 04:11PM Form SC 13G VIVEVE MEDICAL, INC. Filed by: venBio Select Advisor LLC
Feb 12, 2018 04:10PM Form SC 13G/A IOVANCE BIOTHERAPEUTICS, Filed by: venBio Select Advisor LLC
Feb 9, 2018 12:04PM Form SC 13G Apellis Pharmaceuticals, Filed by: venBio Global Strategic Fund II L.P.
Feb 9, 2018 12:03PM Form SC 13G/A Nabriva Therapeutics Filed by: venBio Global Strategic Fund II L.P.
Feb 8, 2018 11:55AM Form SC 13D Menlo Therapeutics Inc. Filed by: venBio Global Strategic Fund II L.P.
Jan 29, 2018 04:24PM Form 4 Menlo Therapeutics, Inc. For: Jan 25 Filed by: venBio Global Strategic Fund II L.P.
Jan 24, 2018 07:07PM Form 3 Menlo Therapeutics, Inc. For: Jan 24 Filed by: venBio Global Strategic Fund II L.P.
Jan 4, 2018 07:27AM Neurogastrx, Inc. Raises $45M Series A To Bring Lead GI Candidate Through Proof Of Concept
Dec 7, 2017 05:00AM Metacrine Completes Series B Financing to Advance Best-in-Class FXR Program into Clinical Development
Nov 16, 2017 11:47AM Form 4 IMMUNOMEDICS INC For: Nov 14 Filed by: venBio Select Advisor LLC
Nov 15, 2017 05:30PM Form SC 13D/A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
Nov 14, 2017 12:23PM Form 13F-HR venBio Select Advisor For: Sep 30
Nov 13, 2017 04:28PM Form 4 Apellis Pharmaceuticals, For: Nov 13 Filed by: venBio Global Strategic Fund II L.P.
Nov 9, 2017 04:10PM Immunomedics Announces First Quarter Fiscal 2018 Results and Provides Corporate Update
Nov 8, 2017 08:35PM Form 3 Apellis Pharmaceuticals, For: Nov 08 Filed by: venBio Global Strategic Fund II L.P.
Oct 26, 2017 03:05PM Schulte Roth & Zabel Holds 8th Annual Shareholder Activism Conference
Oct 11, 2017 02:12PM Form D/A venBio Select Fund Ltd.
Oct 11, 2017 02:09PM Form D/A venBio Select Fund LLC
View More Recent Stories View Older Stories